1. Home
  2. BXBL vs AVLN Comparison

BXBL vs AVLN Comparison

Compare BXBL & AVLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BOXABL Inc. Common stock

BXBL

BOXABL Inc. Common stock

HOLD

Current Price

$3.00

Market Cap

1.4B

ML Signal

HOLD

Logo Avalyn Pharma Inc. Common Stock

AVLN

Avalyn Pharma Inc. Common Stock

SELL

Current Price

$26.01

Market Cap

1.3B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
BXBL
AVLN
Founded
2017
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Homebuilding
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.3B
IPO Year
2023
2026

Fundamental Metrics

Financial Performance
Metric
BXBL
AVLN
Price
$3.00
$26.01
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
★ $61.80
AVG Volume (30 Days)
72.3K
★ 266.3K
Earning Date
11-12-2026
11-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.75
$22.24
52 Week High
$5.42
$40.17

Technical Indicators

Market Signals
Indicator
BXBL
AVLN
Relative Strength Index (RSI) 34.65 45.32
Support Level N/A $24.90
Resistance Level $4.60 $30.45
Average True Range (ATR) 0.22 1.73
MACD 0.01 0.45
Stochastic Oscillator 41.67 72.23

Price Performance

Historical Comparison
BXBL
AVLN

About BXBL BOXABL Inc. Common stock

BOXABL Inc is engaged in building construction using modern manufacturing processes to create residential and commercial buildings that can be completed in less time and at lower cost than traditional construction. The Company has developed a building system using manufacturing processes and existing technologies and processes developed by the automotive industry. Its products include the Casita and other building solutions using patented folding and shipping technology to transport buildings on existing roadways across large geographic areas.

About AVLN Avalyn Pharma Inc. Common Stock

Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.

Share on Social Networks: